Shares of Atea Pharmaceuticals (NASDAQ: AVIR), a clinical-stage biopharmaceutical company, are falling hard after the company shared disappointing clinical-trial data. Investors are worried about what will become of AT-527, an oral COVID-19 treatment, after failing a phase 2 study. The stock was down 61.9% as of 11:26 a.m. EDT on Tuesday.
Full Answer
Is Atea Pharmaceuticals in the NASDAQ biotech index?
Oct 19, 2021 · Shares of Atea Pharmaceuticals ( AVIR -1.25% ), a clinical-stage biopharmaceutical company, are falling hard after the company shared disappointing clinical-trial …
Should you buy Atea (Avir) stock?
Oct 19, 2021 · The stock was down 61.9% as of 11:26 a.m. EDT on Tuesday. So what Atea Pharmaceuticals and its big pharma partner Roche (OTC: RHHBY) are developing AT-527 as an easy-to-swallow antiviral for COVID-19.
What time is the Atea conference call today?
Find the latest Atea Pharmaceuticals, Inc. (AVIR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Where can I watch Atea pharmaceuticals live webcast?
Apr 07, 2022 · Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test finance.yahoo.com - October 19 at 7:31 PM Atea Pharmaceuticals is Now Oversold (AVIR)
What happened
Shares of Atea Pharmaceuticals (NASDAQ: AVIR), a clinical-stage biopharmaceutical company, are falling hard after the company shared disappointing clinical-trial data. Investors are worried about what will become of AT-527, an oral COVID-19 treatment, after failing a phase 2 study. The stock was down 61.9% as of 11:26 a.m. EDT on Tuesday.
So what
Atea Pharmaceuticals and its big pharma partner Roche (OTC: RHHBY) are developing AT-527 as an easy-to-swallow antiviral for COVID-19. Unfortunately, treatment with the antiviral didn't lower the amount of circulating SARS-CoV-2 virus for mild or moderate patients when measured against patients who received a placebo.
Now what
In collaboration with Roche, Atea Pharmaceuticals is running a phase 3 study with around 1,400 mild-to-moderate COVID-19 patients. Atea Pharmaceuticals will try to modify the phase 3 trial to include more high-risk patients.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
What is Atea Pharmaceuticals?
ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation. About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos (t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com. Contacts Jonae BarnesSVP, Investor Relations and Corporate [email protected] Will O’ConnorStern Investor Relations [email protected]
Is AT 527 a direct orally administered drug?
Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19. Atea retains rights to commercialize AT-527 in the U.S., and Roche has the exclusive right to commercialize AT-527 outside of the U.S. AT-527 is an orally administered, direct. #N#. #N#.
Is AT 527 a direct drug?
AT-527 is an orally administered, direct. GlobeNewswire • last month.
Who is AT 527?
Atea retains rights to commercialize AT-527 in the U.S., and Roche has the exclusive right to commercialize AT-527 outside of the U.S. AT-527 is an orally administered, direct
NASDAQ: AVIR
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Were warning signs there for investors all along?
This month, as Merck ( MRK -3.07% ) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals ( AVIR 7.24% ) stock saw a significant drop.
Did timing and trial design predetermine outcomes?
In order to begin, one must compare the Merck and Atea trials. Both examined patients with mild to moderate COVID-19 that were initially well enough to be treated at home outside of the hospital.
NASDAQ: AVIR
Looking at the trial designs, the inclusion of risk factors was right there for all of us to see the entire time. And while vaccine status was not disclosed, at the initiation of Merck's trial, on Oct. 5, 2020, there were no approved vaccines. The vaccine rollout had just begun when Atea started its trial on Jan. 14, 2021.
Endpoints matter
Being a phase 2 trial, Atea used reduction in viral load as an endpoint. The endpoint we all ultimately care about, the frequency of complications related to COVID-19, was a secondary endpoint. Kudos to the company for this patient-centered secondary endpoint.
So where does this leave Atea?
Atea has a rather bare cupboard beyond its SARS-CoV-2 program. It does have a hepatitis C treatment in phase 2 trials, which currently shows as an eight-week trial.
Fundamentals of biotech research
This current trial failure with Atea should serve as an example. It's possible a company can learn from its blunders but investors must know how to maneuver in these situations, especially if this is the worst-case scenario. When a company is going all-in on one particular program (in this case, COVID-19), it is high-risk, high-reward.
Did Timing and Trial Design Predetermine Outcomes?
Endpoints Matter
- Being a phase 2 trial, Atea used reduction in viral load as an endpoint. The endpoint we all ultimately care about, the frequency of complications related to COVID-19, was a secondary endpoint. Kudos to the company for this patient-centered secondary endpoint. Merck's phase 3 trial went with one of the most patient-oriented primary outcomes there i...
So Where Does This Leave Atea?
- Atea has a rather bare cupboard beyond its SARS-CoV-2 program. It does have a hepatitis C treatment in phase 2 trials, which currently shows as an eight-week trial. Unfortunately, this does not significantly differentiate the product from AbbVie's Mavyret, which sold $442 million in the most recent quarter and also uses an eight-week treatment period. I'm not particularly hopeful a…
Fundamentals of Biotech Research
- This current trial failure with Atea should serve as an example. It's possible a company can learn from its blunders but investors must know how to maneuver in these situations, especially if this is the worst-case scenario. When a company is going all-in on one particular program (in this case, COVID-19), it is high-risk, high-reward. There are a few ways to minimize the risks, though. …